CN112075504A - Infant formula milk powder for enhancing immunity - Google Patents
Infant formula milk powder for enhancing immunity Download PDFInfo
- Publication number
- CN112075504A CN112075504A CN202011064571.3A CN202011064571A CN112075504A CN 112075504 A CN112075504 A CN 112075504A CN 202011064571 A CN202011064571 A CN 202011064571A CN 112075504 A CN112075504 A CN 112075504A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- infant formula
- milk powder
- immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/04—Whey; Whey preparations containing non-milk components as source of fats or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of food, and particularly discloses infant formula milk powder for enhancing immunity, which comprises raw materials for preparing effective components of cow milk, lactose, desalted whey powder subjected to partial enzymolysis, 1, 3-dioleate-2-palmitic acid triglyceride, soybean oil, concentrated whey protein powder, linseed oil, galacto-oligosaccharide, anhydrous cream, fructo-oligosaccharide, phospholipid, arachidonic acid powder, compound mineral substances, fish oil powder, compound vitamins, lactoferrin, calcium carbonate, osteopontin, potassium hydroxide, choline chloride, nucleotide and lactobacillus paracasei N1115. The composition of the infant formula milk powder for enhancing the immunity provided by the invention is close to breast milk, so that the nutrition required by the growth and development of infants is ensured, the immunity of the infants is enhanced, and the infection and illness of newborns are prevented. The invention is suitable for infants of 0-6 months, in particular to newborns with low resistance.
Description
Technical Field
The invention belongs to the field of food, and relates to milk powder, in particular to infant formula milk powder for enhancing immunity.
Background
Breast milk provides the ideal nutritional component for the newborn, and is the most important source of nutrients and bioactive components for the growth and development of infants and for protection against external bacterial and viral insults before the infants can themselves ingest and digest other foods. The World Health Organization (WHO) recommends that the infant is fed with pure breast milk within the first 6 months after birth and the breast milk is fed for 2 years or more, however, the breast milk feeding rate in China is still low at present, and the infant formula milk powder is particularly important as a breast milk substitute in the infant group lacking the breast milk feeding.
The composition of breast milk is extremely complex, besides protein, fat, carbohydrate, mineral, vitamin and water, a large amount of bioactive components for enhancing the immunity of infants exist, the content of lactoferrin in the breast milk is 90-800 mg/100mL, and the content of osteopontin is 13.5-328.1 mg/100 mL. Compared with breast milk, the ratio of various nutrient components in cow milk is greatly different, wherein the variety of bioactive components is less and the content is low, the lactoferrin content in cow milk is 2-500 mg/100mL, and the osteopontin content is 1.8 mg/100 mL. Therefore, the content of active protein in cow milk is far lower than that of breast milk, so that the infants eating the common cow milk powder are more easily infected by external pathogenic microorganisms to become sick in the early growth stage.
Disclosure of Invention
The invention aims to provide infant formula milk powder for enhancing immunity aiming at infants so as to enhance the immunity of artificially fed infants.
In order to achieve the purpose, the invention adopts the following technical scheme:
an infant formula milk powder for enhancing immunity comprises, by weight, 60-75 parts of cow milk, 8-12 parts of lactose, 5-8 parts of partially-hydrolyzed desalted whey powder, 3-6 parts of 1, 3-dioleate-2-palmitic acid triglyceride, 2-4 parts of soybean oil, 1-3 parts of concentrated whey protein powder, 1-3 parts of linseed oil, 0.5-1.5 parts of galacto-oligosaccharide, 0.4-1 part of anhydrous cream, 0.1-0.5 part of fructo-oligosaccharide, 0.1-0.3 part of phospholipid, 0.1-0.3 part of peanut powder, 0.1-0.3 part of compound mineral, 0.1-0.2 part of fish oil powder, 0.1-0.2 part of compound vitamin, 0.1-0.2 part of lactoferrin, 0.05-0.1 part of calcium carbonate, 0.025-0.05 part of osteopontin, 0.025 part of calcium carbonate, 0.01-0.05 part of potassium hydroxide, 0.01-0.05 part of choline chloride, 0.01-0.05 part of nucleotide and 0.01-0.05 part of lactobacillus paracasei N1115.
As a limitation: the raw materials for preparing the effective components also comprise 0.005-0.01 part of ganglioside by weight.
As a further limitation: the degree of enzymatic hydrolysis of the partially enzymatically hydrolyzed desalted whey powder was 10%.
As yet a further limitation: the content of Lactobacillus paracasei N1115 is 1 × 1011-1×1012 CFU/g。
As a further limitation: the adding proportion of the lactoferrin to the osteopontin in the raw materials for preparing the effective components is 4:1 in parts by weight.
The lactobacillus paracasei N1115 related in the formula is separated and screened from traditional fermented milk products of Mongolia in China, has been preserved in the strain preservation center of the institute of microbiology of Chinese academy of sciences in 3 months of 2011, and has the preservation number of CGMCC No. 4691. The gene sequence of lactobacillus paracasei N1115 has been disclosed in chinese patent application No. 2011103570588 entitled "lactobacillus casei N1115, its immunomodulatory effect and use".
Due to the adoption of the scheme, compared with the prior art, the invention has the beneficial effects that:
(1) the lactoferrin, the osteopontin and the lactobacillus paracasei N1115 are added into the infant formula milk powder for enhancing the immunity, and the lactoferrin, the osteopontin and the lactobacillus paracasei N1115 are synergistic, so that the immunity can be enhanced, and the morbidity of a newborn is reduced; in addition, the linseed oil and the 1, 3-dioleic acid-2-palmitic acid triglyceride are added into the milk powder, so that the contents of alpha-linolenic acid and sn-2-palmitic acid are improved, the composition of the milk powder is closer to that of fatty acid in breast milk, the nutrition required by the growth and development of infants is ensured, and the healthy development of intestinal tracts is promoted;
(2) the infant formula milk powder for enhancing immunity provided by the invention is added with two prebiotics, namely fructo-oligosaccharide and galacto-oligosaccharide, so that the proliferation of bifidobacteria in intestinal tracts is promoted, the intestinal development and maturity of infants are promoted, and the immune function of infants is enhanced, so that the infants are protected from being infected and diseased;
(3) the ganglioside is added into the infant formula milk powder for enhancing the immunity, so that the intestinal flora of the newborn is adjusted, the development of the intestinal immune system of the newborn is promoted, and the early infection of the infant is prevented;
(4) the infant formula milk powder for enhancing immunity provided by the invention is added with the partially-enzymolyzed desalted whey powder, so that main protein allergens in the milk powder can be effectively destroyed, the total IgE level in serum is reduced, and the allergenicity of whey protein is reduced.
In conclusion, the composition of the infant formula milk powder for enhancing immunity provided by the invention is close to breast milk, so that nutrition required by growth and development of infants is ensured, the immunity of newborns is enhanced, and the infection and illness of the newborns are prevented.
The invention is suitable for infants of 0-6 months, in particular to newborns with low resistance.
Drawings
The invention is described in further detail below with reference to the figures and the embodiments.
FIG. 1 is a graph showing the results of varying concentrations of IL-18 secretion in combination with lactoferrin, osteopontin and Lactobacillus paracasei N1115 in example 7 of the present invention;
FIG. 2 is a graph showing the results of the weight change of a mouse in example 8 of the present invention;
FIG. 3 is a graph showing the results of measurement of mouse fecal sIgA according to example 8 of the present invention.
Detailed Description
The present invention is further described with reference to the following examples, but it should be understood by those skilled in the art that the present invention is not limited to the following examples, and any modifications and variations based on the specific examples of the present invention are within the scope of the claims of the present invention.
Examples 1-6 Immunity-enhancing infant formula milk powder
Examples 1-6 are a method of preparing an infant formula milk powder for enhancing immunity, respectively, the raw material composition of which is shown in table 1, and the process parameters for preparing the milk powder are shown in table 2.
The preparation method comprises the following steps:
s1, standardizing raw milk, separating impurities, pasteurizing at 70-75 ℃ for 15-18S to obtain milk, adding lactose, desalted whey powder with partial enzymolysis degree of 10%, 1, 3-dioleate-2-palmitic acid triglyceride, soybean oil, concentrated whey protein powder, linseed oil, galacto-oligosaccharide, anhydrous cream, fructo-oligosaccharide, phospholipid, compound mineral substances, compound vitamins, calcium carbonate, potassium hydroxide and choline chloride into the milk, stirring and mixing uniformly, and dissolving sufficiently to obtain a material A;
s2, preheating the material A to 58-62 ℃, homogenizing under the pressure of 15-18MPa, and then heating to 85-95 ℃ for sterilization for 20-30S to obtain a material B;
s3, evaporating and concentrating the material B through a four-effect falling film to prepare concentrated milk C, wherein the density of the concentrated milk C is 1100-1150kg/m3；
S4, pumping the concentrated milk C into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 170-;
s5, adding arachidonic acid powder, fish oil powder, lactoferrin, osteopontin, nucleotide, lactobacillus paracasei N1115 and ganglioside into the material D, and mixing uniformly to obtain the infant formula milk powder for enhancing immunity.
TABLE 1 examples 1-6 raw materials for infant formula milk powder for boosting immunity
The content of lactobacillus paracasei N1115 in examples 1-6 was in order: 2X 1011 CFU/g、1×1011 CFU/g、3×1011 CFU/g、1×1012 CFU/g、6×1011 CFU/g、8×1011CFU/g. The multivitamins of examples 1-6 contain the following components: vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B2, vitamin B6, vitamin B12, nicotinamide, folic acid, vitamin C, biotin, and pantothenic acid; the compound mineral comprises the following components: sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine and selenium.
TABLE 2 Process parameters for examples 1-6
Example 7 in vitro cell model evaluation
In this example, different Lactoferrin (LF) and Osteopontin (OPN) addition ratios are set for the composite lactobacillus paracasei N1115, and the dominance ratios of the ingredients are evaluated by an in vitro cell model, specifically the evaluation method is as follows:
caco-2 cells were cultured for 2 hours in a serum-free medium, and then incubated for 72 hours at 37 ℃ in a cell culture medium containing 1% fetal calf serum supplemented with Lactoferrin (LF), Osteopontin (OPN) and Lactobacillus paracasei N1115, respectively, and LF-OPN mixture at different concentration ratios combined with Lactobacillus paracasei N1115 (the specific addition concentration is shown in Table 3, diluted 20 times). The cell culture medium was collected, concentrated by an ultrafiltration centrifuge tube, and the content of IL-18 was measured using an ELISA kit.
TABLE 3 mixture composition
Referring to FIG. 1, it is shown that lactoferrin, osteopontin, and N1115 can promote secretion of IL-18 by Caco-2 cells in FIG. 1. The combination of the three components showed the best effect of promoting IL-18 secretion, and the best effect was obtained when LF: OPN =4: 1.
Example 8 testing of an Immunity-enhancing infant milk formula
In this example, 30 suckling mice are randomly divided into 2 groups, which are an experimental group and a control group, each group comprises 15 suckling mice, the infant formula milk powder for enhancing immunity in the experimental group of the gavage example 1, the common infant milk powder (without the addition of the composition of lactoferrin, osteopontin and lactobacillus paracasei N1115, and the addition of other raw and auxiliary materials are the same as those in the example 1) with the same dose in the control group of the gavage, the test period is 14 days, the weight of the suckling mice is measured every 2 days, and the feces are taken for sIgA detection at 0 day, 7 days and 14 days, and the results are shown in fig. 2 and 3.
As can be seen from FIG. 2, the body weight of both the experimental group and the control group continuously increased with the time after birth, and at 7 days and 14 days, the body weight of the experimental group suckling mice was significantly higher than that of the control group suckling mice, and the growth rate of the experimental group suckling mice was significantly higher than that of the control group. Therefore, the infant formula added with the composition of lactoferrin, osteopontin and lactobacillus paracasei N1115 can better promote the growth and development of mice.
As can be seen from the graph 3, the fecal sIgA concentration of the suckling mice in the control group and the experimental group shows a gradually rising trend along with the time extension, which indicates that the intestinal tracts of the two groups of mice are normally developed, and compared with the control group, the fecal sIgA concentration of the experimental group of suckling mice is obviously raised at 14 days, which indicates that the infant formula milk powder added with the composition of lactoferrin, osteopontin and lactobacillus paracasei N1115 can promote the intestinal tract immunity and enhance the resistance.
Claims (8)
1. The infant formula milk powder for enhancing immunity is characterized by comprising, by weight, 60-75 parts of cow milk, 8-12 parts of lactose, 5-8 parts of partially-enzymolyzed desalted whey powder, 3-6 parts of 1, 3-dioleate-2-palmitic acid triglyceride, 2-4 parts of soybean oil, 1-3 parts of concentrated whey protein powder, 1-3 parts of linseed oil, 0.5-1.5 parts of galactose, 0.4-1 part of anhydrous cream, 0.1-0.5 part of fructo-oligosaccharide, 0.1-0.3 part of phospholipid, 0.1-0.3 part of arachidonic acid powder, 0.1-0.3 part of compound mineral substance, 0.1-0.2 part of fish oil powder, 0.1-0.2 part of compound vitamin, 0.1-0.2 part of lactoferrin, 0.05-0.1 part of calcium carbonate, 0.1 part of calcium carbonate, 0.025-0.05 part of osteopontin, 0.01-0.05 part of potassium hydroxide, 0.01-0.05 part of choline chloride, 0.01-0.05 part of nucleotide and 0.01-0.05 part of lactobacillus paracasei N1115.
2. The infant formula milk powder for improving immunity according to claim 1, wherein the raw material composition for preparing the effective components further comprises 0.005-0.01 parts by weight of ganglioside.
3. The enhanced immunity infant formula milk powder according to claim 1 or 2, wherein the partially enzymatically hydrolyzed desalted whey powder has an enzymatic hydrolysis degree of 10%.
4. The enhanced immunity infant formula milk powder of claim 1 or 2 wherein the lactobacillus paracasei N1115 is present in an amount of 1 x 1011-1×1012 CFU/g。
5. The enhanced immunity infant formula of claim 3The milk powder is characterized in that the content of lactobacillus paracasei N1115 is 1 multiplied by 1011-1×1012 CFU/g。
6. The infant formula milk powder for improving immunity according to any one of claims 1, 2 and 5, wherein the addition ratio of lactoferrin to osteopontin in the raw materials for preparing the active ingredients is 4:1 in parts by weight.
7. The infant formula milk powder for improving immunity according to claim 3, wherein the addition ratio of lactoferrin to osteopontin in the raw materials for preparing the effective ingredients is 4:1 in parts by weight.
8. The infant formula milk powder for improving immunity according to claim 4, wherein the addition ratio of lactoferrin to osteopontin in the raw materials for preparing the effective ingredients is 4:1 in parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011064571.3A CN112075504A (en) | 2020-09-30 | 2020-09-30 | Infant formula milk powder for enhancing immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011064571.3A CN112075504A (en) | 2020-09-30 | 2020-09-30 | Infant formula milk powder for enhancing immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112075504A true CN112075504A (en) | 2020-12-15 |
Family
ID=73730890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011064571.3A Withdrawn CN112075504A (en) | 2020-09-30 | 2020-09-30 | Infant formula milk powder for enhancing immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112075504A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068591A (en) * | 2022-07-06 | 2022-09-20 | 合生元（广州）健康产品有限公司 | Probiotic composition containing osteopontin |
| CN115989871A (en) * | 2021-10-20 | 2023-04-21 | 安琪纽特股份有限公司 | A growth-promoting composition and its preparation method and application |
| CN116172191A (en) * | 2023-03-17 | 2023-05-30 | 内蒙古伊利实业集团股份有限公司 | Nutritional composition and its application in preparing anti-inflammatory products |
| CN116807021A (en) * | 2022-11-30 | 2023-09-29 | 内蒙古伊利实业集团股份有限公司 | Use of a nutritional component in the preparation of products with anti-enteritis and/or protection of intestinal barrier integrity |
| WO2024114729A1 (en) * | 2022-11-30 | 2024-06-06 | 内蒙古伊利实业集团股份有限公司 | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof |
| CN118633735A (en) * | 2024-05-27 | 2024-09-13 | 合生元（广州）健康产品有限公司 | Application of the composition in preparing a product for improving constipation |
-
2020
- 2020-09-30 CN CN202011064571.3A patent/CN112075504A/en not_active Withdrawn
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115989871A (en) * | 2021-10-20 | 2023-04-21 | 安琪纽特股份有限公司 | A growth-promoting composition and its preparation method and application |
| CN115068591A (en) * | 2022-07-06 | 2022-09-20 | 合生元（广州）健康产品有限公司 | Probiotic composition containing osteopontin |
| CN116807021A (en) * | 2022-11-30 | 2023-09-29 | 内蒙古伊利实业集团股份有限公司 | Use of a nutritional component in the preparation of products with anti-enteritis and/or protection of intestinal barrier integrity |
| WO2024114729A1 (en) * | 2022-11-30 | 2024-06-06 | 内蒙古伊利实业集团股份有限公司 | Composition for resisting enteritis and/or protecting integrity of intestinal barrier, and use thereof |
| CN116172191A (en) * | 2023-03-17 | 2023-05-30 | 内蒙古伊利实业集团股份有限公司 | Nutritional composition and its application in preparing anti-inflammatory products |
| CN118633735A (en) * | 2024-05-27 | 2024-09-13 | 合生元（广州）健康产品有限公司 | Application of the composition in preparing a product for improving constipation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112075504A (en) | Infant formula milk powder for enhancing immunity | |
| CN1838888A (en) | Infant or follow-on formula | |
| RU2600877C2 (en) | Fermented infant formula | |
| CN110179121A (en) | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application | |
| CN110506793A (en) | Breast milk baby formula milk powder containing profitable probliotics and preparation method thereof | |
| CN107594279A (en) | A kind of probiotic powder solid beverage and preparation method thereof | |
| CN104381681A (en) | Antibiotic-free pig creep conservation general concentrate and complete feed thereof | |
| CN112167360A (en) | Low-sensitization infant formula goat milk powder | |
| CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
| CN112535218A (en) | Maternal emulsified infant formula milk powder for promoting intelligence development and intestinal health and preparation method and application thereof | |
| CN111548972A (en) | Lactobacillus plantarum with helicobacter pylori resistance function and application thereof | |
| CN112790250A (en) | Infant formula milk powder for promoting intestinal health and preparation method thereof | |
| CN114223729B (en) | Application of bifidobacterium longum subspecies infantis and breast milk oligosaccharide composition in formula milk powder | |
| CN107668208A (en) | A kind of formula milk for promoting intestinal health | |
| CN110122865A (en) | A kind of supplementary food for infants and preparation method thereof adding breast milk oligosaccharide | |
| CN110692741A (en) | Formula milk powder for promoting bone growth and preparation method thereof | |
| CN110959867A (en) | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof | |
| CN119138609B (en) | The use of human milk oligosaccharides to improve the intestinal flora of mothers and infants | |
| CN112167348A (en) | Formula milk powder for promoting growth and development of children and preparation method thereof | |
| CN108669563A (en) | A kind of composition, its application and strengthen immunity, the product for improving allergy | |
| CN1305383C (en) | Active bifidobacteria contained milk powder and its preparation method | |
| CN112535217A (en) | Maternal emulsified hypoallergenic fresh and alive infant formula milk and preparation method thereof | |
| CN117179234B (en) | Instant food composition and preparation method thereof | |
| CN107897380A (en) | A kind of close to breast milk and have the function of prebiotic babies ' formula milk powder of enteron aisle and preparation method thereof | |
| CN111972497A (en) | Children formula milk powder capable of improving immunity and constipation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20201215 |
|
| WW01 | Invention patent application withdrawn after publication |